Overview

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects

Status:
Not yet recruiting
Trial end date:
2024-01-02
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the appropriate dose of rimegepant in Japanese subjects, as well as to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the acute treatment of migraine.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.